13F Data
13F filer · CIK 2106181

Kalehua Capital Management LLC

DALLAS, TX · filing since Q4 2025 · last filing Aug 19, 2026
Reported value
$313.5M
+$53.5M vs prior
Positions
26
New / sold out
8 / 7
Added / reduced
5 / 3
Turnover
22.7%
buys $65.2M · sells $67.9M
Top-10 weight
70.1%

Biggest buys vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
NewKaryopharm Therapeutics Inc+1,371,288–+$13.4M
NewInflarx Nv+5,795,538–+$13.0M
NewCyclerion Therapeutics Inc+3,302,700–+$11.2M
AddedVeradermics Inc+42,816+17.2%+$5.3M
AddedKorro Bio Inc+295,664+270.3%+$3.9M
NewNuvectis Pharma Inc+200,000–+$3.7M
NewMilestone Pharmaceuticals Inc+2,538,474–+$3.4M
AddedAclaris Therapeutics Inc+494,809+15.6%+$2.6M
NewAdlai Nortye+226,415–+$2.6M
AddedInhibikase Therapeutics Inc+1,149,282+17.7%+$2.3M
3 more rows. Subscribe for $29/month to see every row, download the data and use the API.

Biggest sells vs Q1 2026

ChangeSecurityShares changeChange %Est. trade value
Sold outRelay Therapeutics Inc-1,802,914-100.0%$-17.9M
ReducedUniqure Nv-343,997-68.4%$-15.8M
ReducedEA SERIES TRUST-110,512-32.8%$-12.9M
Sold outOruka Therapeutics Inc-237,048-100.0%$-11.6M
Sold outPepGen Inc-1,729,961-100.0%$-3.1M
Sold outTenaya Therapeutics Inc-4,000,000-100.0%$-2.8M
Sold outKalaris Therapeutics Inc-271,170-100.0%$-1.6M
ReducedInstil Bio Inc-123,679-38.3%$-951.1K
Sold outDiaMedica Therapeutics Inc-124,976-100.0%$-846.1K
Sold outLONGEVERON INC-347,539-100.0%$-361.4K

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2025: $101.1MQ1 2026: $259.9MQ2 2026: $313.5M
Q4 2025Q2 2026

Holdings · Q2 2026

#SecuritySharesValueWeight
1Veradermics IncCOMMON STOCK291,390$35.8M11.43%
2X4 Pharmaceuticals IncCOM NEW7,445,680$34.8M11.09%
3EA SERIES TRUSTALPHA ARCH 1-3226,188$26.5M8.45%
4Compass Pathways PlcSPONSORED ADS1,639,384$23.2M7.40%
5Surrozen IncCOM NEW770,356$20.0M6.38%
6Aclaris Therapeutics IncCOM3,664,730$19.4M6.18%
7Sionna Therapeutics IncCOM394,144$17.3M5.53%
8Inhibikase Therapeutics IncCOM NEW7,643,780$15.5M4.95%
9Pharvaris NVCOM397,544$13.7M4.39%
10Karyopharm Therapeutics IncCOM NEW1,371,288$13.4M4.27%
16 more rows. Subscribe for $29/month to see every row, download the data and use the API.